ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine in Advanced Endometrial Cancer
July 28, 2020Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) today announced that the first patients have started treatment in its Phase II study evaluating the safety and efficacy of its investigational antibody-drug conjugate (ADC) [vic-]trastuzumab duocarma -
ImmunoGen's antibody-drug conjugate mirvetuximab soravtansine misses main goal of Phase III ovarian cancer study
March 03, 2019ImmunoGen announced Friday that a Phase III study of the experimental antibody-drug conjugate (ADC) mirvetuximab soravtansine in patients with folate receptor (FR) alpha-positive, platinum-resistant ovarian cancer failed to meet its primary endpoint of pr
Pharma Sources Insight January 2025
